opdivo set top estim
may reinforc keytruda leadership i-o space continu
expect keytruda gain traction increas lead opdivo
current estim opdivo keytruda sale
us tad higher consensu
respect global vs consensu
respect
adjust extrapol symphoni sale indic higher
may monthli keytruda us sale ahead opdivo us sale
expand lead keytruda pick march
opdivo adjust qtd symphoni sale estim typic over/
understat extrapol june month sale base histor
trend estim full sale around keytruda
almost opdivo cs consensu
estim expect market share gain keytruda continu
come month support mainli uptak nsclc
hand continu expect opdivo sale nsclc pressur
lung cancer patient previous would come
chemotherapi instead come keytruda unlik
end anoth agent line treatment per bristol
comment call first line patient treat
i-o drug presum entir keytruda patient like
end opdivo second line treatment outsid clinic trial
set ultim shrink opdivo market size nsclc
stage set adjuv market battl lung cancer remain
major area focu due substanti market potenti compani
also highlight indic driven growth
i-o product emphas increas
contribut non-lung indic consist
highlight opportun beyond lung cancer contribut
significantli revenu stream i-o approv far
metastat set also highlight adjuv immuno-
oncolog note potenti market opportun see
adjuv i-o set far opdivo keytruda approv
adjuv melanoma nine adjuv trial readout six tumor
type next three year trial on-going
adjuvant/neoadjuv set expect discuss
opportun keytruda adjuvant/neoadjuv set
indic investor day tomorrow
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau univers toronto symphoni iqvia monthli sale trend
us million pleas note addit day may compar feb influenc qoq growth
symphoni health cs estim analysi
us million
iqvia iqvia nation sale perspectivetm cs estim analysi
us million
us million
analyt cs estim analysi
first order analyt cs estim analysi
us million
us million
analyt cs estim analysi
first order analyt cs estim analysi
us million iqvia sale compris one month sale symphoni sale compris two month sale
compani data symphoni health iqvia iqvia nation sale perspectivetm cs estim analysi
us million iqvia sale compris one month sale symphoni sale compris two month sale
compani data symphoni health iqvia iqvia nation sale perspectivetm cs estim analysi
figur keytruda opdivo quarterli us sale trend
us million
figur adjust symphoni sale under/overstat base histor trend
us million
opdivo
revenu
market sell administr
equiti net incom affili
allianc licens incom
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
revenu
amort intang
equiti incom affili
total incom expens
provis incom tax
compani mention price
